A new frontier: FDA approvals for gene therapy in sickle cell disease.
作者信息
Leonard Alexis, Tisdale John F
机构信息
Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
出版信息
Mol Ther. 2024 Feb 7;32(2):264-267. doi: 10.1016/j.ymthe.2024.01.015. Epub 2024 Jan 20.
Abstract
摘要
相似文献
1
A new frontier: FDA approvals for gene therapy in sickle cell disease.一个新的前沿领域：美国食品药品监督管理局批准用于镰状细胞病的基因疗法。
Mol Ther. 2024 Feb 7;32(2):264-267. doi: 10.1016/j.ymthe.2024.01.015. Epub 2024 Jan 20.
2
Approval of the First CRISPR-Cas9 Gene Editing Therapy for Sickle Cell Disease.首款用于镰状细胞病的CRISPR-Cas9基因编辑疗法获批。
Clin Chem. 2024 Oct 3;70(10):1298. doi: 10.1093/clinchem/hvae038.
3
Food and Drug Administration Approval of Glutamine for Sickle Cell Disease: Success and Precautions in Glutamine Research.美国食品药品监督管理局批准谷氨酰胺用于镰状细胞病：谷氨酰胺研究的成功与注意事项
JPEN J Parenter Enteral Nutr. 2017 Aug;41(6):912-917. doi: 10.1177/0148607117727271. Epub 2017 Aug 31.
4
Recent and anticipated novel drug approvals for 2023 and 2024.2023 年和 2024 年新获批药物一览。
Am J Health Syst Pharm. 2023 Nov 22;80(23):1729-1732. doi: 10.1093/ajhp/zxad220.
5
Gene therapy targets sickle-cell disease.基因疗法针对镰状细胞病。
Nature. 2018 Dec;564(7735):S12-S13. doi: 10.1038/d41586-018-07646-w.
6
An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States.美国镰状细胞病基因治疗的伦理与财务义务
Ann Intern Med. 2024 Jan;177(1):85-86. doi: 10.7326/M23-2428. Epub 2023 Dec 5.
7
Emerging disease-modifying therapies for sickle cell disease.新兴的镰状细胞病治疗方法。
Haematologica. 2019 Sep;104(9):1710-1719. doi: 10.3324/haematol.2018.207357. Epub 2019 Aug 14.
8
Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy.镰状细胞病获批药物包括首款CRISPR基因编辑疗法。
JAMA. 2024 Jan 23;331(4):280. doi: 10.1001/jama.2023.26113.
9
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia.社论：CRISPR-Cas9 治疗性基因编辑治疗镰状细胞病和输血依赖型β-地中海贫血的首次监管批准。
Med Sci Monit. 2024 Mar 1;30:e944204. doi: 10.12659/MSM.944204.
10
Sickle cell disease: progress towards combination drug therapy.镰状细胞病：联合药物治疗的进展。
Br J Haematol. 2021 Jul;194(2):240-251. doi: 10.1111/bjh.17312. Epub 2021 Jan 20.
引用本文的文献
1
Bioengineering approaches to trained immunity: Physiologic targets and therapeutic strategies.训练有素的免疫的生物工程方法：生理靶点与治疗策略。
Elife. 2025 Jul 23;14:e106339. doi: 10.7554/eLife.106339.
2
Hospital Readmissions Among People With Sickle Cell Disease.镰状细胞病患者的医院再入院情况。
JAMA Netw Open. 2025 Jun 2;8(6):e2517974. doi: 10.1001/jamanetworkopen.2025.17974.
3
Clinical advances in gene, cell, and RNA therapies.基因、细胞和RNA疗法的临床进展。
Mol Ther. 2025 Jun 4;33(6):2311. doi: 10.1016/j.ymthe.2025.05.012. Epub 2025 May 20.
4
Comparative Proteomic Analysis Reveals Altered Ciliary Proteins in Sickle Cell Disease.比较蛋白质组学分析揭示镰状细胞病中纤毛蛋白的改变
J Proteome Res. 2025 Jun 6;24(6):2981-2995. doi: 10.1021/acs.jproteome.5c00168. Epub 2025 May 15.
5
From bench to bedside: the future of stable lentiviral packaging cell lines in gene therapy.从实验台到病床边：稳定慢病毒包装细胞系在基因治疗中的未来。
Gene Ther. 2025 Apr 26. doi: 10.1038/s41434-025-00537-6.
6
Multilayered HIV-1 resistance in HSPCs through CCR5 Knockout and B cell secretion of HIV-inhibiting antibodies.通过CCR5基因敲除和B细胞分泌HIV抑制抗体在造血干细胞中实现多层HIV-1抗性。
Nat Commun. 2025 Apr 1;16(1):3103. doi: 10.1038/s41467-025-58371-8.
7
Balancing benefits and burdens: a systematic review on ethical and social dimensions of gene and cell therapies for hereditary blood diseases.权衡利弊：关于遗传性血液疾病基因和细胞疗法伦理与社会层面的系统评价
BMC Med Ethics. 2025 Mar 14;26(1):36. doi: 10.1186/s12910-025-01188-3.
8
Epigenetic regulation in muscle-invasive urothelial carcinoma of the bladder in the dog, a translational model of human cancer.犬膀胱肌层浸润性尿路上皮癌中的表观遗传调控，一种人类癌症的转化模型。
Vet Oncol. 2024;1. doi: 10.1186/s44356-024-00011-2. Epub 2024 Nov 20.
9
Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells.将嵌合抗原受体无病毒CRISPR敲入KLRC1可产生高效的GD2特异性自然杀伤细胞。
Mol Ther. 2025 Mar 5;33(3):1014-1030. doi: 10.1016/j.ymthe.2025.01.024. Epub 2025 Jan 14.
10
Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets.病毒和非病毒系统将基因治疗递送至临床靶标。
Int J Mol Sci. 2024 Jul 4;25(13):7333. doi: 10.3390/ijms25137333.
本文引用的文献
1
Human genetic diversity alters off-target outcomes of therapeutic gene editing.人类遗传多样性改变了治疗性基因编辑的脱靶效应。
Nat Genet. 2023 Jan;55(1):34-43. doi: 10.1038/s41588-022-01257-y. Epub 2022 Dec 15.
2
Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.洛沃细胞基因治疗镰状细胞病：HGB-206 研究初始组的治疗过程演变和结果。
Am J Hematol. 2023 Jan;98(1):11-22. doi: 10.1002/ajh.26741. Epub 2022 Oct 10.
3
Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism.造血系统恶性肿瘤在成人移植物失败和混合嵌合体后 HCT 后 SCD 中的发生率增加。
Blood. 2022 Dec 8;140(23):2514-2518. doi: 10.1182/blood.2022017960.
4
Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease.镰状细胞病基因治疗后发生的急性髓系白血病病例。
N Engl J Med. 2022 Jan 13;386(2):138-147. doi: 10.1056/NEJMoa2109167. Epub 2021 Dec 12.
5
CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease.利用CRISPR-Cas9诱导胎儿血红蛋白治疗镰状细胞病。
Mol Ther Methods Clin Dev. 2021 Oct 1;23:276-285. doi: 10.1016/j.omtm.2021.09.010. eCollection 2021 Dec 10.
6
Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither.基因治疗镰状细胞病后的白血病：插入突变，白消安，还是两者都不是。
Blood. 2021 Sep 16;138(11):942-947. doi: 10.1182/blood.2021011488.
7
A pause in gene therapy: Reflecting on the unique challenges of sickle cell disease.基因治疗的停顿：反思镰状细胞病的独特挑战
Mol Ther. 2021 Apr 7;29(4):1355-1356. doi: 10.1016/j.ymthe.2021.03.010. Epub 2021 Mar 19.
8
Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects.建立成人镰状细胞病的医疗服务可及性：定义照护模式、基本要素和经济方面。
Blood Adv. 2020 Aug 25;4(16):3804-3813. doi: 10.1182/bloodadvances.2020001743.
9
Sickle cell anemia, a molecular disease.镰状细胞贫血，一种分子疾病。
Science. 1949 Apr 29;109(2835):443.
10
Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin.在表达慢病毒编码的人β-珠蛋白的β地中海贫血小鼠中进行治疗性血红蛋白合成。
Nature. 2000 Jul 6;406(6791):82-6. doi: 10.1038/35017565.
Zotero 插件